Hematologic Malignancies

News

GENUINE improvements: Ublituximab plus ibrutinib for CLL

Author:

Kate O’Rourke

Publish date: April 21, 2021

Ublituximab plus ibrutinib was superior to ibrutinib alone for patients with relapsed or refractory high-risk...

• Read More

News

CLL patients: Diagnostic difficulties, treatment confusion with COVID-19

Author:

Mark S. Lesney, PhD

Publish date: April 19, 2021

The overall prevalence of CLL and COVID-19 concurrence was around 0.6%, according to the review.

• Read More

News

COVID-19 vaccine failure in patients with blood cancers

Author:

Pam Harrison

Publish date: April 14, 2021

Nearly half did not produce antibodies even though they had all received both doses of one of the new mRNA COVID...

• Read More

News

Steroids can be stopped in some older multiple myeloma patients

Author:

Roxanne Nelson, RN, BSN

Publish date: April 1, 2021

There was no difference in progression-free and overall survival between two groups, with and without steroids...

• Read More

News

First CAR T-cell therapy for multiple myeloma: Abecma

Author:

Zosia Chustecka

Publish date: March 29, 2021

“The results of this trial represent a true turning point in the treatment of this disease.”

• Read More

News

Concern over response to COVID-19 in patients with blood cancers

Author:

Liam Davenport

Publish date: January 12, 2021

Among patients with hematologic cancers, immune responses were less pronounced and were highly variable,...

• Read More

Case Reports

Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations

Author:

Ryan S. Chiang, MD

Daphne R. Friedman, MD

Kelsey McHugh, MD

Sendhilnathan Ramalingam, MD

Vishal Vashistha, MD

Targeting and monitoring several acute myeloid leukemia mutations sequentially provides insights into optimal treatment plans.

• Read More

News

Experts offer roadmap for treating CLL during the pandemic

Author:

Victoria Stern, MA

Publish date: December 23, 2020

The expert recommendations are divided into three main categories: patients who are newly diagnosed with CLL but...

• Read More

Conference Coverage

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma

Author:

Neil Osterweil

Publish date: December 15, 2020

Fifteen of 16 patients with relapsed/refractory multiple myeloma had strong responses to therapy with BCMA- and...

• Read More

Conference Coverage

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies

Author:

Walter Alexander

Publish date: December 11, 2020

Once-daily oral DTRM-555 shows encouraging activity in Richter’s transformation and DLBCL.

• Read More

Pages

• « first
• …
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• …
• last »